KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC

The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology.

Programme

Thursday, 15 July 2021

19:30-20:30 CEST

Welcome and introduction, Scientific background and context

Fabrice André, Gustave Roussy, Villejuif, France

KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC

Peter Schmid, Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University London, London, UK

Critical analysis and perspectives

Giuseppe Curigliano, IEO - European Institute of Oncology, Milan, Italy 

Discussion and Q&A (i)

Faculty and online audience

Friday, 16 July 2021

13:15-14:25 CEST (07:15 EDT / 19:15 SGT / 20:15 KST / 21:15 AEST)

Virtual Plenary Expert Insights: Webcast of 15 July presentations, Discussion and Q&A (ii)

Faculty and online audience:

Chair: Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Australia

Peter Schmid, Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University London, London, UK

Giuseppe Curigliano, IEO - European Institute of Oncology, Milan, Italy

Lisa Carey, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA

Sung-Bae Kim, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

Yoon-Sim Yap, NCCS - National Cancer Centre Singapore